Gantenerumab

N/A

Report date: 2026/04/16 20:00:17

Base Information

Drug NameGantenerumab
Drug Alias Name冈特奈卢单抗gantenerumabum更汀芦单抗gantenerumabMAb-31 +[8] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionBeta amyloid A4 protein inhibitors
TargetsBeta amyloid A4 protein
Therapy Area/IndicationsAlzheimer DiseaseDementia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[38] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaDiscontinued
Originator CompaniesChugai Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesWashington University School Of MedicineF. Hoffmann-La Roche Ltd
Inactive CompaniesChugai Pharmaceutical Co LtdGenentech IncRoche (China) Holding Ltd
Active IndicationsAlzheimer DiseaseDementia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG